The Innovel Shanghai DreamCenter recently commenced operations in Waigaoqiao. As a shared experimental platform for the pharmaceutical and fine chemical industries, the center provides innovative teams with a HASS (Hardware and Software as a Service) supply chain model, offering comprehensive support spanning technology R&D and business incubation.
Innovel is a domestic brand specializing in laboratory automation equipment and consumables. With a focus on intelligent biopharmaceutical production and equipment development, the company has established a core technology system with fully independent intellectual property rights. To date, it has successfully launched over 30 standardized products, delivering tailored solutions for drug discovery and development, synthetic biology research, cell and gene therapy, and clinical diagnostics.
Located in U-LAB Phase II in Waigaoqiao, the 5,800-square-meter facility is equipped with multiple integrated automated laboratory platforms, including a synthetic biology experimental platform and a full-process plasmid preparation platform.
By leveraging the center’s high-end equipment, experienced professional teams, and mature operational expertise, settled enterprises can access automated infrastructure and applications tailored to diverse scenarios without the need for upfront infrastructure investment. The 24-hour non-stop operation of intelligent integrated hardware systems will help accelerate project timelines, shorten innovation cycles, reduce R&D costs, and speed up product commercialization.
"Behind every technological breakthrough—from lab inspiration to industrial application—lies the relentless pursuit of scientists and engineers to change the world. We aim to stand alongside every innovator, merging biopharmaceuticals with smart manufacturing to become a driving force in industry advancement," said Chen Hao, founder and CEO of Innovel.
Currently, the Waigaoqiao Free Trade Zone has developed a robust industrial cluster covering high-end medical devices, innovative drug development, and cell and gene therapy, supported by its strengths in cross-border R&D, bonded manufacturing, and global supply chains.
